chemotherapy

Description Results NMA

PFS 0.67 [0.51; 0.89]

ORR 2.91 [1.18; 7.15]

OS 0.85 [0.62; 1.17]

Pemetrexed plus carboplatin (n=-9)

vs.

pemetrexed (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase 2

(n=34)

vs.

(n=33)

Sample size: 34/33

Primary endpoint:

FU duration:

pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone (n=283)

vs.

docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days (n=288)

Sample size: 283/288

Primary endpoint: overall survival

FU duration:

carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). (n=106)

vs.

docetaxel (75 mg/m(2)). (n=105)

Sample size: 106/105

Primary endpoint: survival without treatment-emergent grade 3/4 toxicity

FU duration:

pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone (n=132)

vs.

docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone (n=128)

Sample size: 132/128

Primary endpoint: overall response rate (ORR)

FU duration:

pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles (n=74)

vs.

docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles (n=72)

Sample size: 74/72

Primary endpoint: time to disease progression (TTP).

FU duration:

pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle (n=107)

vs.

docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle (n=104)

open-label

Sample size: 107/104

Primary endpoint:

FU duration:

ORR 2.42 [1.42; 4.12]

OS 0.89 [0.73; 1.09]

PFS 0.83 [0.68; 1.01]

Vandetanib plus pemetrexed (n=-9)

vs.

pemetrexed (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase 3